QT VASCULAR LTD.
(Company Registration No. 201305911K)
(Incorporated in Singapore)

ELECTRONIC DESPATCH OF SCHEME DOCUMENT AND ALTERNATIVE ARRANGEMENTS RELATING TO THE SCHEME MEETING TO BE HELD ON 24 JUNE 2022

---

1. BACKGROUND

The board of directors ("**Board**" or "**Directors**") of QT Vascular Ltd. ("**Company**") refers to the announcements made by the Company on 2 March 2022, 22 March 2022, 11 May 2022 and 19 May 2022 ("**Previous Announcements**") in relation to, *inter alia*, the proposed restructuring of the Company for the proposed transfer of listing status of the Company to Quantum Healthcare Limited, the Proposed Options Variation and the Proposed Awards Variation, by way of a scheme of arrangement under Section 210 of the Companies Act 1967 ("**Scheme**").

Unless otherwise defined, all capitalised terms used and not defined herein shall have the same meanings given to them in the Previous Announcements and the Scheme Document (as defined below).

2. ELECTRONIC DESPATCH OF SCHEME DOCUMENT

2.1 Electronic Despatch of Scheme Document

The Board wishes to announce that the Company has today issued to the Shareholders a scheme document ("**Scheme Document**") dated 1 June 2022 by electronic means via publication on the website of the SGX-ST at www.sgx.com/securities/company-announcements and the website of the Company at https://www.qtvascular.com.

The Scheme Document contains, *inter alia*, the following:

(a) details of the Scheme, including the recommendation of the independent Directors in relation to the Scheme; and

(b) the notice of the Scheme Meeting ("**Notice**") to be convened and held on Friday, 24 June 2022 at 9.30 a.m. by way of electronic means, for the purpose of considering and, if thought fit, passing, with or without modifications, the resolution relating to the Scheme referred to in the Notice ("**Scheme Resolution**").

2.2 Electronic Copies of Scheme Document

Due to the current COVID-19 situation in Singapore, no printed copies of the Scheme Document, the Notice and the Proxy Form will be despatched to the Shareholders.

Electronic copies of the Scheme Document (enclosing the Notice and the Proxy Form) are available on:

(a) the SGXNET at www.sgx.com/securities/company-announcements; and

(b) the website of the Company at https://www.qtvascular.com.

A Shareholder will still need an internet browser and PDF reader to view these documents on

the SGXNET and the Company's website.

2.3 Overseas Shareholders

The applicability of the Scheme to Shareholders whose addresses are outside of Singapore (as shown in the Register of Members of the Company or, as the case may be, in the records of The Central Depository (Pte) Limited) (collectively, "**Overseas Shareholders**") may be affected by the laws of the relevant overseas jurisdictions. Accordingly, all Overseas Shareholders should inform themselves about, and observe, any applicable legal requirements in their own jurisdictions.

The Scheme Document will not be sent to any Overseas Shareholders due to the potential restrictions on sending such documents into the relevant overseas jurisdictions. For the avoidance of doubt, the Scheme is proposed to all Shareholders and applies to all Shareholders, including those Shareholders to whom this Scheme Document has not been and will not be sent.

3. DATE, TIME AND CONDUCT OF THE SCHEME MEETING

The Board wishes to announce that pursuant to the COVID-19 (Temporary Measures) (Alternative Arrangements for Meetings for Companies, Variable Capital Companies, Business Trusts, Unit Trusts and Debenture Holders) Order 2020, the Scheme Meeting will be convened and held by way of electronic means on **Friday, 24 June 2022 at 9.30 a.m.**

Pursuant to the order of the Court dated 19 May 2022 granting liberty to the Company to convene the Scheme Meeting and containing further orders in relation to the conduct of the Scheme Meeting ("**Scheme Meeting Court Order**"), Mr Ng Fook Ai Victor, or failing him, any director of the Company, shall act as Chairman of the Scheme Meeting and to report the results thereof to the Court.

The Company will endeavour to address all substantial and relevant questions relating to the Scheme Resolution received by **9.30 a.m. on 14 June 2022** by publishing responses on the Company's website and on SGXNET prior to the Scheme Meeting by **9.30 a.m. on 19 June 2022** or by addressing such questions during the Scheme Meeting. In addition to the foregoing, Shareholders will also be able to ask questions "live" via the online chat box function during the Scheme Meeting. The Company will, within one (1) month after the date of the Scheme Meeting, publish the minutes of the Scheme Meeting on the Company's website and on the SGXNET, and the minutes will include the responses to the substantial and relevant questions which are addressed during the Scheme Meeting.

4. NO PERSONAL ATTENDANCE AT THE SCHEME MEETING

Shareholders will not be able to attend the Scheme Meeting in person due to the current COVID-19 situation in Singapore.

5. VOTING

Shareholders who wish to vote at the Scheme Meeting can either:

(a) pre-register online at https://registration.ryt-poll.com/home/index/qtvascular-sm by **9:30 a.m. on 22 June 2022** being not less than 48 hours before the time for holding the Scheme Meeting to:

- attend and vote (in real time) at the Scheme Meeting via electronic means; or
- appoint a proxy(ies) to attend and vote (in real time) at the Scheme Meeting via

electronic means on their behalf and provide the requisite details of the proxy(ies),

(b) if they do not wish to attend or appoint a proxy(ies) to attend and vote (in real time) at the Scheme Meeting, submit a Proxy Form to appoint the Chairman of the Scheme Meeting to vote on their behalf.

For the avoidance of doubt, Shareholders who have pre-registered to appoint a proxy(ies) to attend and vote at the Scheme Meeting via electronic means on their behalf must also submit a completed Proxy Form for the appointment of such proxy(ies). All Proxy Forms must be received by the Company by **9:30 a.m. on 22 June 2022**, being not less than 48 hours before the time for holding the Scheme Meeting.

Where a Shareholder has chosen to appoint a proxy(ies) (including the Chairman of the Scheme Meeting as proxy, where applicable), the Shareholder should specifically direct the proxy(ies) (including the Chairman of the Scheme Meeting as proxy, where applicable) on how he/she/it is to vote for or vote against (or abstain from voting) on the Scheme Resolution. If no specific direction as to voting is given, (aa) (in the case of the appointment of the Chairman of the Scheme Meeting as proxy), such appointment of the Chairman will be treated as invalid; and (bb) (in the case of appointment of anyone other than the Chairman of the Scheme Meeting as proxy(ies), the proxy(ies) will vote or abstain from voting at his/her/its discretion. For the avoidance of doubt, pre-registration is not required if a Shareholder only intends to appoint the Chairman of the Scheme Meeting as proxy and does not intend to attend the Scheme Meeting.

A Shareholder may only cast all the votes he/she/it uses at the Scheme Meeting in one way, save that a Shareholder who is a relevant intermediary[1] or a Depository Agent (hereinafter, an "**Intermediary**") need not cast all the votes it uses in the same way, provided that each vote is exercised in relation to a different Share. For the purposes of satisfying the condition under section 210(3AB)(a) of the Companies Act, the Company shall treat an Intermediary that casts votes both for and against the Scheme as follows:

- the Company shall treat the Intermediary as casting one (1) vote in favour of the Scheme if the Intermediary casts more votes for the Scheme than against the Scheme;

- the Company shall treat the Intermediary as casting one (1) vote against the Scheme if the Intermediary casts more votes against the Scheme than for the Scheme; and

- the Company shall treat the Intermediary as casting one (1) vote for and one (1) vote against the Scheme if the Intermediary casts equal votes for and against the Scheme.

In compliance with the Scheme Meeting Court Order, the Company will write to each Intermediary to (a) inform it of the foregoing arrangements and will request each Intermediary to provide a breakdown of the voting instructions it receives in respect of the Scheme Resolution on an aggregated basis for the purposes of ascertaining the number of votes cast for and against the Scheme by each Intermediary, and (b) provide instructions in relation to the submission of Proxy Form by each Intermediary.

[1] **A "relevant intermediary" means**:
(a) a banking corporation licenced under the Banking Act (Chapter 19 of Singapore) or a wholly-owned subsidiary of such a banking corporation, whose business includes the provision of nominee services and who holds shares in that capacity;
(b) a person holding a capital markets services licence to provide custodial services for securities under the Securities and Futures Act 2001 who holds shares in that capacity; or
(c) the Central Provident Fund Board established by the Central Provident Fund Act 1953, in respect of shares purchased under the subsidiary legislation made under that Act providing for the making of investments from the contributions and interest standing to the credit of members of the Central Provident Fund, if the CPF Board holds those shares in the capacity of an intermediary pursuant to or in accordance with that subsidiary legislation.

6. ALTERNATIVE ARRANGEMENTS FOR PARTICIPATION IN THE SCHEME MEETING

Alternative arrangements have been put in place to allow Shareholders to participate in the Scheme Meeting by:

(a) observing and/or listening to the Scheme Meeting proceedings via "live" audio-and-visual webcast or "live" audio-only stream;

(b) submitting questions in advance of the Scheme Meeting or during the Scheme Meeting via an online chat box; and/or

(c) voting (in real time via electronic means (either personally or via appointment of proxy) or by the appointment of the Chairman of the Scheme Meeting as proxy).

Further details on alternative arrangements relating to the attendance at the Scheme Meeting (pursuant to the Scheme Meeting Court Order) via electronic means (including arrangements by which the meeting can be electronically accessed via "live" audio-and-video webcast or "live" audio-only stream), submission of questions to the Chairman of the Scheme Meeting in advance of, or "live" at, the Scheme Meeting, and/or voting (in real time via electronic means (either personally or via appointment of proxy) or by the appointment of the Chairman of the Scheme Meeting as proxy) at the Scheme Meeting, are set out in Appendix A to the Scheme Document.

7. KEY DATES/DEADLINES

The table below sets out the key dates/deadlines for Shareholders and SRS Investors to note:

Key Dates / Deadlines	Actions
1 June 2022 (Wednesday)	Pre-registration begins for "live" audio-and-video webcast / "live" audio-only stream of the proceedings of the Scheme Meeting. Shareholders who wish to appoint a proxy(ies) (other than the Chairman of the Scheme Meeting) must, in addition to completing and submitting an instrument appointing a proxy(ies), pre-register their appointed proxy(ies) at the pre-registration website at https://registration.ryt-poll.com/home/index/qtvascular-sm.
9.30 a.m. on 14 June 2022 (Tuesday)	Deadline for all Shareholders and SRS Investors to submit questions in relation to the Scheme Resolution to be tabled at the Scheme Meeting, in advance of the Scheme Meeting, by email to kelvin.tong@quantumhealthcare.com.sg or by post to the registered office of the Company at 16 Raffles Quay, #41-07, Hong Leong Building, Singapore 048581.
9.30 a.m. on 15 June 2022 (Wednesday)	Deadline for SRS Investors, who wish to vote, to approach their SRS Agent Banks to submit their voting instructions. SRS Investors may vote "live" via electronic means at the Scheme Meeting if they are appointed as proxies by their respective SRS Agent Banks, and should contact their respective SRS Agent Banks if they have any queries regarding their appointment as proxies.

9.30 a.m. on 19 June 2022 (Sunday)	Deadline for the Company to respond to substantial and relevant questions received in relation to the Scheme Resolution by 9.30 a.m. on 14 June 2022.
9.30 a.m. on 22 June 2022 (Wednesday)	Deadline for all Shareholders and SRS Investors to pre-register for the "live" audio-and-video webcast or "live" audio-only stream of the proceedings of the Scheme Meeting.
9.30 a.m. on 22 June 2022 (Wednesday)	Deadline for all Shareholders to submit Proxy Forms via email to kelvin.tong@quantumhealthcare.com.sg or sg.is.proxy@sg.tricorglobal.com or by post to the office of the Share Registrar.
9.30 a.m. on 23 June 2022 (Thursday)	Authenticated Shareholders (including SRS Investors) or, where applicable, their appointed proxies who have (or have been) pre-registered for the "live" audio-and-video webcast or "live" audio-only stream of the proceedings of the Scheme Meeting will receive an email, which will contain user ID and password details as well as instructions on how to access the same ("**Confirmation Email**"). Shareholders (including SRS Investors) or, where applicable, their appointed proxies who do not receive the Confirmation Email by 9.30 a.m. on 23 June 2022 (Thursday), but have pre-registered for the "live" audio-and-video webcast or "live" audio-only stream of the proceedings of the Scheme Meeting by the deadline should contact the Company's polling agent, via email at qtvascular-sm@ryt-poll.com.
Date and time of Scheme Meeting 9.30 a.m. on 24 June 2022 (Friday)	• Click on the link in the Confirmation Email and follow the instructions to access the "live" audio-and-video webcast of the proceedings of the Scheme Meeting; or • Call the telephone number and follow the instructions in the Confirmation Email to access the "live" audio-only stream of the proceedings of the Scheme Meeting. Shareholders (including SRS Investors) or, where applicable, their appointed proxies must access the Scheme Meeting proceedings via the "live" audio-visual webcast in order to ask questions and vote "live" at the Scheme Meeting.

An indicative timetable for the events which are scheduled to take place after the Scheme Meeting is set out on page 12 of the Scheme Document.

8. IMPORTANT REMINDER

Due to the constantly evolving COVID-19 situation in Singapore, the Company may be required to change the arrangements for the Scheme Meeting at short notice. Shareholders and persons (including SRS Investors) who hold Shares through a relevant intermediary are advised to regularly check the Company's website at https://www.qtvascular.com or announcements released by the Company on SGXNET for updates on the status of the Scheme Meeting.

9. DIRECTORS' RESPONSIBILITY STATEMENT

The Directors collectively and individually accept full responsibility for the accuracy of the information given in this announcement and confirm, after making all reasonable enquiries, that

to the best of their knowledge and belief, this announcement constitutes full and true disclosure of all material facts about the Scheme as set out herein, the Company and its subsidiaries, and the Directors are not aware of any facts the omission of which would make any statement in this announcement misleading.

Where information in this announcement has been extracted from published or otherwise publicly available sources or obtained from a named source, the sole responsibility of the Directors has been to ensure that such information has been accurately and correctly extracted from those sources and/or reproduced in this announcement in its proper form and context.

By order of the Board
QT VASCULAR LTD.

Thomas Tan Gim Chua
Chief Executive Officer
1 June 2022

---

*This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. ("**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited ("**Exchange**") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Ms Lim Hui Ling, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.